XML 23 R13.htm IDEA: XBRL DOCUMENT v3.19.1
Stock-based Compensation
3 Months Ended
Mar. 31, 2019
Stock-based Compensation [Abstract]  
Stock-based Compensation

6 - STOCK-BASED COMPENSATION 



On April 22, 2014, the stockholders of the Corporation approved the 2014 Equity Incentive Plan (“2014 Plan”). Upon approval of the 2014 Plan, no further awards could be made under the 2006 Stock Compensation Plan (“2006 Plan”).



2014 Plan. Under the 2014 Plan, awards may be granted to employees and non-employee directors as non-qualified stock options (“NQSOs”), stock appreciation rights (“SARs”), restricted stock awards, RSUs, or any combination thereof, any of which may be subject to performance-based vesting conditions. Awards may also be granted to employees as incentive stock options (“ISOs”). The exercise price of stock options and SARs granted under the 2014 Plan may not be less than the fair market value of the Corporation’s common stock on the date the stock option or SAR is granted. The 2014 Plan is administered by the Compensation Committee of the Board of Directors. Almost all of the awards granted to date under the 2014 Plan are RSUs. All awards granted under the 2014 Plan will immediately vest upon an involuntary termination following a change in control, total and permanent disability, as defined, or death, and with certain exceptions, will immediately vest in the event of retirement, as defined.

 

The Corporation has 2,250,000 shares of common stock reserved for awards under the 2014 Plan. Awards granted under the 2006 Plan that expire or are forfeited after April 22, 2014 will be added to the number of shares of common stock reserved for issuance of awards under the 2014 Plan. All of the 2,250,000 shares may be issued upon the exercise of stock options or SARs. A maximum of 787,500 shares may be issued as restricted stock awards or upon the conversion of RSUs. At March 31, 2019,  1,751,778 equity awards remain available to be granted under the 2014 Plan of which 298,633 may be granted as restricted stock awards or RSUs.



Details of RSUs. The following table summarizes the vesting schedule of RSUs outstanding at March 31, 2019 by the year they were originally granted.







 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

 

Granted During the Year Ended December 31,



Total

 

2019

 

2018

 

2017

 

2016

Number of RSUs:

 

 

 

 

 

 

 

 

 

Granted during the year

379,435 

 

107,144 

 

70,688 

 

94,329 

 

107,274 

Outstanding at March 31, 2019

220,890 

 

107,144 

 

44,338 

 

66,408 

 

3,000 



 

 

 

 

 

 

 

 

 

Scheduled to vest during:

 

 

 

 

 

 

 

 

 

2019

94,126 

 

23,535 

 

14,359 

 

53,232 

 

3,000 

2020

54,414 

 

35,706 

 

8,782 

 

9,926 

 

 —

2021

36,632 

 

12,185 

 

21,197 

 

3,250 

 

 —

2022

35,718 

 

35,718 

 

 —

 

 —

 

 —



220,890 

 

107,144 

 

44,338 

 

66,408 

 

3,000 



The RSUs in the table above include performance-based RSUs with vesting based on the financial performance of the Corporation in 2019 and 2020 and service-based RSUs with various service-based vesting periods. The grant date fair value of RSUs awarded in 2016 is equal to the market price of the shares underlying the awards on the grant date. The grant date fair value of RSUs awarded in 2017, 2018 and 2019 is equal to the market price of the shares underlying the awards on the grant date, discounted for dividends that are not paid on these RSUs.



The following table presents a summary of RSUs outstanding at March 31, 2019 and changes during the three month period then ended.







 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

Weighted-

 

 

 



 

 

 

Weighted-

 

Average

 

Aggregate



 

 

 

Average

 

Remaining

 

Intrinsic



 

Number of

 

Grant-Date

 

Contractual

 

Value



 

RSUs

 

Fair Value

 

Term (yrs.)

 

(in thousands)

Outstanding at January 1, 2019

 

215,084 

 

$

23.79 

 

 

 

 

 

 

Granted

 

107,144 

 

 

19.48 

 

 

 

 

 

 

Converted

 

(101,338)

 

 

20.79 

 

 

 

 

 

 

Outstanding at March 31, 2019

 

220,890 

 

$

23.08 

 

 

1.41 

 

$

4,844 

Vested and Convertible at March 31, 2019

 

 —

 

$

 —

 

 

 —

 

$

 —



The performance-based RSUs granted in 2019 and 2018 have a maximum payout potential of 1.50 shares of the Corporation’s common stock for each RSU awarded. Performance-based RSU’s granted in 2017 have a maximum payout potential of 1.25 shares for each RSU awarded. All other RSUs outstanding at March 31, 2019 have a maximum payout potential of one share of the Corporation’s common stock for each RSU awarded. All of the RSUs outstanding at March 31, 2019 are currently expected to vest and become convertible in the future. The total intrinsic value of RSUs converted during the first three months of 2019 and 2018 was $2,107,000 and $2,884,000, respectively. 



2006 Plan. The 2006 Plan was approved by the stockholders of the Corporation on April 18, 2006. The 2006 Plan permitted the granting of stock options, SARs, restricted stock awards and RSUs to employees and non-employee directors. Through December 31, 2011, equity grants to executive officers and directors under the 2006 Plan consisted of a combination of NQSOs and RSUs, while equity grants to other officers consisted solely of NQSOs. Beginning in 2012, equity grants under the 2006 Plan consisted solely of RSUs. Stock options granted under the 2006 Plan have a five year vesting period and a ten year term.



Fair Value of Stock Options. The grant date fair value of options was estimated on the date of grant using the Black-Scholes option pricing model. Substantially all outstanding stock options were expensed in prior years.



Stock Option Activity. The following table presents a summary of options outstanding at March 31, 2019, and changes during the three month period then ended.





 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

Weighted-

 

 

 



 

 

 

Weighted-

 

Average

 

Aggregate



 

 

 

Average

 

Remaining

 

Intrinsic



 

Number of

 

Exercise

 

Contractual

 

Value



 

Options

 

Price

 

Term (yrs.)

 

(in thousands)

Outstanding at January 1, 2019

 

96,112 

 

$

11.80 

 

 

 

 

 

 

Exercised

 

(19,656)

 

 

10.32 

 

 

 

 

 

 

Forfeited or expired

 

 —

 

 

 —

 

 

 

 

 

 

Outstanding at March 31, 2019

 

76,456 

 

$

12.18 

 

 

1.43 

 

$

745 

Exercisable at March 31, 2019

 

76,156 

 

$

12.16 

 

 

1.42 

 

$

744 



All options outstanding at March 31, 2019 are either fully vested or expected to vest. The total intrinsic value of options exercised during the first three months of 2019 and 2018 was $203,000 and $205,000, respectively. Cash received from option exercises in the first three months of 2019 and 2018 was $203,000 and $96,000, respectively. Tax benefits from stock option exercises for the three months ended March 31, 2019 and 2018 were $61,000 and $62,000, respectively.



Compensation Expense. The Corporation recorded compensation expense for share-based payments of $1,295,000 and $1,128,000 and recorded related income tax benefits of $390,000 and $340,000 for the three months ended March 31, 2019 and 2018, respectively.



Unrecognized Compensation Cost. As of March 31, 2019, there was $1,797,000 of total unrecognized compensation cost related to non-vested equity awards comprised of $1,000 for stock options and $1,796,000 for RSUs. The total cost is expected to be recognized over a weighted-average period of 1.3 years, which is based on weighted-average periods of 1.2 years and 1.3 years for stock options and RSUs, respectively. 



Other. No cash was used to settle stock options during the first three months of 2019 or 2018. The Corporation uses newly issued shares to settle stock option exercises and for the conversion of RSUs. During the three months ended March 31, 2019 and 2018, 1,462 and 557 shares, respectively, of the Corporation’s common stock were issued to members of the Board of Directors in payment of director fees.